AAV-IL-27 |
|
Vaxjo ID |
234 |
|
Vaccine Adjuvant Name |
AAV-IL-27 |
|
Adjuvant VO ID |
VO_0005721
|
|
Description |
A gene therapy vector using AAV to deliver IL-27, an immunomodulatory cytokine with anti-tumor properties |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
adeno-associated virus (AAV-IL-27) |
|
Structure |
rAAV vector encoding IL-27; IL-27 is a heterodimeric cytokine composed of EBI3 and p28 subunits |
|
Preparation |
Produced by packaging IL-27 gene into an AAV vector and administered via i.m. or intra-tumoral injection in mice |
|
Dosage |
2 × 10¹¹ DRP/mouse in preclinical models |
|
Function |
Systemically delivered IL-27 by adeno-associated virus (AAV-IL-27) is very well tolerized by mice and exhibits potent anti-tumor activity in a variety of tumor models. |
|
Safety |
Well-tolerated in mice; low toxicity even at high systemic IL-27 levels. No signs of autoimmune damage observed |
| References |
Liu et al., 2020: Liu JQ, Zhu J, Hu A, Zhang A, Yang C, Yu J, Ghoshal K, Basu S, Bai XF. Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?. American journal of cancer research. 2020; 10(11); 3565-3574. [PubMed: 33294255].
|
